Logomix Raises 2.8 Billion Yen to Accelerate Commercialization of Cell Engineering-Based Bio Products and U.S. Expansion
On July 30, 2025, Logomix Inc. announced the completion of a 2.8 billion yen (approximately $18 million USD) funding round.
Logomix will use the newly raised capital to accelerate the commercialization of its multi-industry bio products, built upon its proprietary cellular function engineering technologies. In particular, the company plans to strengthen its strategic expansion into the U.S. market, focusing on cell and regenerative therapies.
By positioning its proprietary Geno-Writing™ Platform as a foundational layer—much like Arm architecture in the semiconductor space—Logomix aims to become a core enabler of innovation and industrial competitiveness within the global bioeconomy.
Investors
The round included participation from existing investors such as Angel Bridge, JAFCO, UTokyo IPC, and Sand Hill Angels (U.S.), as well as new investors: Globis Capital Partners, Itochu Technology Ventures, Delight Ventures, Mirai Souzou Investments, Norinchukin Capital, JST, MUFG Capital, Aozora Corporate Investment, SMBC, Resona Bank, and several individual investors.
Additionally, the company has received government grants:
- NEDO DTSU Program (STS Phase) in 2024
- JST A-STEP Program in 2025
U.S. Expansion and Partnerships
Logomix has launched a strategic partnership with Somite Therapeutics Inc., a U.S.-based TechBio leader that raised $47 million in its Series A round. The collaboration integrates machine learning to predict and enhance therapeutic outcomes.
The company has also initiated a joint research project with Prof. Ron Weiss’s lab at MIT, focusing on regenerative medicine and next-generation cell therapies—further demonstrating the broad applicability of its Geno-Writing™ Platform.
To reinforce its U.S. leadership, Logomix has appointed two esteemed experts as scientific advisors:
- Dr. Ramy Ibrahim, former Chief Medical Officer at the Parker Institute for Cancer Immunotherapy
- Dr. Mitchell Finer, co-founder and former President of R&D at ElevateBio
Their deep expertise in genome editing, iPSC-derived therapies, and clinical translation will significantly support Logomix’s vision to develop scalable, transformative cell therapies.
Company Background
Logomix’s mission is to “maximize the potential of cells through cellular system engineering.” Unlike traditional gene editing tools like CRISPR—which modify only portions of the genome—Geno-Writing™ enables large-scale genome reconstruction, endowing cells and microbes with novel functions. This breakthrough approach empowers applications in therapeutic development, sustainable biofuels, and high-performance biomaterials.
Logomix envisions its platform becoming a universal operating system for cellular engineering, allowing diverse partners to design and reprogram genomes for innovative product development. Since its previous 500 million yen funding round in 2023, Logomix has achieved several milestones, including:
- Success in synthetic yeast chromosome research led by Chief Scientific Officer Dr. Yasunori Aizawa
- Presentation of stem cell therapy applications at the 2025 ISSCR Annual Meeting
- Expansion of global partnerships through joint development and licensing with U.S. and European firms
Editor’s Note
Have you heard of the Institute of Science Tokyo?
It is a new national university established in October 2024 through the merger of Tokyo Institute of Technology and Tokyo Medical and Dental University.
As one of Japan’s most prestigious and competitive institutions, it is known for its exceptional technological capabilities.Moreover, the investors who participated in this funding round are all leading players in the biotech sector, underscoring the strong expectations and momentum surrounding this field.
[Source]